Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026)
Canopy Growth (CGC) posted Liabilities and Shareholders Equity of $815.8 million for Q1 2026, up 2.84% sequentially from $793.2 million in Q4 2025, and up 27.55% YoY from $639.6 million in Q1 2025.
Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Canopy Growth has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $815.8 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 27.55% year-over-year to $815.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (down 8.36% YoY) and the FY2026 annual result came in at $815.8 million, up 27.55% from the prior year.
- Liabilities and Shareholders Equity rose to $815.8 million in Q1 2026 per CGC's latest filing, from $793.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $4.4 billion in Q1 2022 and troughed at $639.6 million in Q1 2025.
- A 5-year average of $1.5 billion and a median of $965.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity tumbled 59.22% in 2023, then advanced 27.55% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $2.2 billion in 2022, then tumbled by 53.88% to $998.8 million in 2023, then decreased by 16.56% to $833.4 million in 2024, then retreated by 4.82% to $793.2 million in 2025, then climbed by 2.84% to $815.8 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $815.8 million, $793.2 million, and $777.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | 798.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 798.05 Mn |
| Mar 31, 2026 | 815.79 Mn |
| Dec 31, 2025 | 793.24 Mn |
| Sep 30, 2025 | 777.38 Mn |
| Jun 30, 2025 | 652.91 Mn |
| Mar 31, 2025 | 639.56 Mn |
| Dec 31, 2024 | 833.41 Mn |
| Sep 30, 2024 | 903.38 Mn |
| Jun 30, 2024 | 940.41 Mn |
| Mar 31, 2024 | 964.99 Mn |
| Dec 31, 2023 | 998.79 Mn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.63 Bn |
| Mar 31, 2023 | 1.80 Bn |
| Dec 31, 2022 | 2.17 Bn |
| Sep 30, 2022 | 2.55 Bn |
| Jun 30, 2022 | 2.75 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 5.01 Bn |
| Sep 30, 2021 | 5.16 Bn |